Shots:

• The P-III SELECT-COMPARE study evaluates the safety and efficacy of Rinvoq (15 mg- qd) vs PBO and Humira (SC- 40mg- every other week) in a ratio (2:2:1) in adult patients with a mod. to sev. active RA who had an inadequate response to MTX and continued a stable background of MTX
• The new analysis showed that the therapy maintained high rates of clinical remission & low disease activity compared with Humira @ 3yrs.- the safety profile was consistent with previously reported and in P-III integrated safety analysis- no new safety risks identified up to 4.5yrs.
• Rinvoq is a selective & reversible JAK inhibitor- approved for three adult rheumatic indications in the EU

  Ref: Abbvie | Image:abbvie